(S,R,S)-MI-1061 can be used for the synthesis of Antibody-Drug Conjugates (ADCs); it is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50 = 4.4 nM; Ki = 0.16 nM) that activates p53 and induces apoptosis in mouse SJSA-1 xenograft tumor tissues, demonstrating antitumor activity.